SUSAN WALLACE: Open Payments
NPI 1740537687 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,566 in 126 payments from 18 companies in 2025. Trend: 2023 $1,483 · 2024 $3,163 · 2025 $2,566
Food & beverage: $2,481Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $813 |
| Aimmune Therapeutics, Inc. | 16 | $318 |
| Madrigal Pharmaceuticals | 9 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $202 |
| Janssen Biotech, Inc. | 6 | $189 |
| Regeneron Healthcare Solutions, Inc. | 5 | $161 |
| QOL Medical, LLC | 6 | $107 |
| Novo Nordisk Inc | 3 | $96 |
| Ardelyx, Inc. | 4 | $88 |
| Lilly USA, LLC | 5 | $82 |
Products named: RINVOQ, ZENPEP, REZDIFFRA, LINZESS, DUPIXENT, TREMFYA, MAVYRET, Sucraid.
Industry payments across MS — which companies pay providers there.
